Search

Background: Gastric cancer (GC) is currently the fifth most common malignancy. Accumulating evidence has recently revealed that maladjustments of diverse long non-coding RNAs may play key roles in multiple genetic and epigenetic phenomena in GC. Long non-coding RNAs (lncRNAs), which are transcriptional products with more than 200 nucleotides, are a subset of non-coding RNAs. LncRNA LOWEG and lncRNA MINCR, as novel lncRNAs, may have roles in GC progression. Objective: This study aimed to examine the clinical and diagnostic significance of lncRNA LOWEG and lncRNA MINCR in GC. Methods: The qRT-PCR technique measured lncRNA LOWEG and lncRNA MINCR expression in GC tissues and matched adjacent marginal tissues. The association between clinicopathological parameters and the expression level of lncRNAs was evaluated. Furthermore, The ROC curve was plotted to assess the diagnostic power of lncRNA LOWEG and lncRNA MINCR as candidate biomarkers in gastric cancer patients. Results: We found that lncRNA LOWEG expression was downregulated in cancerous tissues compared to the adjacent marginal tissues (P-value < 0.0001). LncRNA MINCR expression was upregulated in cancerous tissues compared to adjacent marginal tissues (P-value < 0.0001). Downregulation of lncRNA LOWER and upregulation of lncRNA MINCR did not significantly correlate with clinicopathological parameters. ROC curve analysis showed that lncRNA LOWEG and lncRNA MINCR could be proposed as reliable diagnostic biomarkers in GC. Conclusion: The expression of the lncRNA LOWEG was reduced in tumoral tissues compared to the adjacent marginal tissues, and the expression of lncRNA MINCR increased in tumoral tissues. So, as a result, lncRNAs LOWEG and MINCR could be considered diagnostic biomarkers for GC. [ABSTRACT FROM AUTHOR]

Background: Long non-coding RNAs (lncRNAs) play important roles in lung tumorigenesis. Among different lncRNAs, overexpression of the lncRNA actin filament‐associated protein 1‐antisense RNA 1 (AFAP1-AS1) in lung tumors has been reported in different studies. In the current study, we aimed to investigate the potential value of lncRNA AFAP1-AS1 as a diagnostic biomarker in lung cancer. Ninety samples from patients with lung cancer were collected from Noor-E-Nejat hospital, Tabriz, Iran. The expression of AFAP1-AS1 was assessed using quantitative reverse transcriptase-PCR (qRT-PCR), followed by the ROC curve analysis to investigate the biomarker potency of AFAP1-AS1. Results: Our results revealed an upregulation of AFAP1-AS1 in tumor samples as compared to the adjacent non-tumor tissues. We found a significant positive association between AFAP1-AS1 expression and tumor size, as well as tumor stage. Conclusions: Our results showed overexpression of AFAP1-AS1 and its capacity as a diagnostic biomarker in lung cancer. [ABSTRACT FROM AUTHOR]